Article citationsMore>>

van Harten, A.C., Kester, M.I., Visser, P.J., Blankenstein, M.A., Pijnenburg, Y.A.L., van der Flier, W.M. and Scheltens, P. (2011) Tau and p-tau as CSF biomarkers in de- mentia: A meta-analysis. Clinical Chemistry and Labo- ratory Medicine, 49, 353-366. doi:10.1515/cclm.2011.086

has been cited by the following article:

• TITLE: CSF tau and amyloid β42 levels in Alzheimer’s disease—A meta-analysis

  AUTHORS: Rachna Agarwal, Neelam Chhillar, Vijay Nath Mishra, Chandra Bhushan Tripathi

  KEYWORDS: Alzheimer’s Disease; Dementia; CSF Amyloid β42; CSF Tau; Meta-Analysis

  JOURNAL NAME: Advances in Alzheimer's Disease, Vol.1 No.3, December 27, 2012

  ABSTRACT: Alzheimer’s disease International (ADI) estimates that there are currently 30 million people with dementia in the world. The main objective was to perform meta-analysis of studies of CSF tau and Amyloid β42 (Aβ42) levels in Alzheimer’s disease (AD) patients and controls. In the present study MEDLINE was reviewed from 1995 to 2009, supplemented by citation analysis from retrieved articles to select case control studies. Descriptive statistics showed that median effect size (raw mean difference) of CSF tau and Aβ42 levels were 301 pg/ml (Range: 22 to 614 pg/ml) and –352 pg/ml (Range: –969 to 203 pg/ml) respectively. The pooled effect size CSF tau and Aβ42 was 289.14 pg/ml (95% CI 253.278 to 325.013 pg/ml) and –329.02 pg/ml (95% CI –387.740 to –270.445 pg/ml) respectively. Heterogeneity in effect size of selected studies was present for both parameters (CSF tau: Q statistics = 1816.596, DF = 40, P = 0.000 and CSF Aβ42: Q-statistics = 1259.358, DF = 24, p 42 levels in AD and controls may be considered as potential biomarker along with the clinical phenotype to perform them during high quality diagnostic testing in dementia.